Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy

Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is making high-stakes bets in neurodegenerative diseases to fuel its evolution | In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzheimer’s disease as part of a multi-step roadmap to establish its independent capabilities in the U.S.